Table 1.

Pre- and post- treatment characteristics and pathologic outcomes of NCCN low–& intermediate- risk men undergoing radical prostatectomy at University of Pennsylvania, 1990–2012 (Overall Cohort).

	Caucasian Cohort n=1031	%	African-American Cohort n=234	%	p-Value
Age, Y					0.48†
Median	60		58
mean	59.1		57.8
IQR	54–64		52–62
iPSA ng/ml					0.89†
0–4.0	271	26	59	25
4.01 - 10	659	64	150	65
10.01- 20	101	10	25	11
median	5.1		5.6
mean	5.8		6.2
IQR	4.1 -- 6.7		4.1 -- 7.8
Biopsy Gleason					<0.001*
≤6	948	90	162	67
7(3+4)	103	10	54	23
Clinical Stage					0.63*
T1A-C	583	81	149	85
T2A	111	16	22	12
T2B	8	1	4	2
T2C	12	2	1	1
Year of prostatectomy					0.006†
median	2003		2004
mean	2002.7		2003.7
IQR	1999–2007		2000–2008
Pathologic Stage					0.07*
pT2N0	802	77	175	74
pT3aN0	202	20	44	19
pT3bN0	23	2	13	6
pT4aN0	4	1	2	1
Pathologic Gleason					<0.001*
≤6	596	57	113	46
7(3+4)	229	22	81	36
7(4+3)	35	4	14	7
7(unspecified)	145	14	22	9
8 to 10	26	3	4	2
Gleason upgrading					0.25*
6/7 to 7/(8–10)	369	35	72	30
Adverse pathologic features‡					0.35*
0	757	73	164	69
1	147	15	33	15
≥2	127	12	37	16
Extraprostatic spread	223	22	58	25	0.32*
Seminal Vesicle invasion	27	3	13	6	0.02*
Positive surgical margin	162	16	39	17	0.71*
Radiotherapy	11	1	3	1	0.78*
ADT	35	3	8	3	0.5*

NOTE. Boldfaced values represent statistically signi cant differences between groups.

Abbreviations: iPSA- initial Prostate-specific antigen, IQR- interquartile range;

NCCN- National Comprehensive Cancer Network; ADT- Androgen depravation therapy

^*P value derived from Person’s chi-square test.

^†P value derived from analysis of variance model.

^‡Adverse pathologic features: extraprostatic extension, seminal vesicle invasion, and/or positive surgical margin.